Evidence map›Paper›PMID 32715434›Full record

ArticlePharmacological reports : PR2020

Influence of metformin on HIF-1 pathway in multiple myeloma.

Kinga A Kocemba-Pilarczyk, Sonia Trojan, Barbara Ostrowska, Małgorzata Lasota, Paulina Dudzik, Dorota Kusior, Marta Kot

Open access · hybridAbstract read
In one paragraph

Article in Pharmacological reports : PR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kinga A Kocemba-PilarczykMedical Biochemistry, Jagiellonian University-Medical College, ul. Kopernika 7, 31-034, Kraków, Poland. kinga.kocemba@uj.edu.pl.ORCID http://orcid.org/0000-0002-7119-2412
Sonia TrojanMedical Biochemistry, Jagiellonian University-Medical College, ul. Kopernika 7, 31-034, Kraków, Poland.
Barbara OstrowskaMedical Biochemistry, Jagiellonian University-Medical College, ul. Kopernika 7, 31-034, Kraków, Poland.
Małgorzata LasotaDepartment of Transplantation, Jagiellonian University Medical College, Kraków, Poland.
Paulina DudzikMedical Biochemistry, Jagiellonian University-Medical College, ul. Kopernika 7, 31-034, Kraków, Poland.
Dorota KusiorMedical Biochemistry, Jagiellonian University-Medical College, ul. Kopernika 7, 31-034, Kraków, Poland.
Marta KotDepartment of Transplantation, Jagiellonian University Medical College, Kraków, Poland.
Jagiellonian University · PL

Funding

The work presented in the paper was supported by National Science Center grant nr 2013/09/N/NZ1/01873
6 · The paper itself

Abstract

backgroundMultiple myeloma (MM) is defined as plasma cells malignancy, developing in the bone marrow. At the beginning of the disease, the malignant plasma cells are dependent on bone marrow microenvironment, providing growth and survival factors. Importantly, the recent studies pointed hypoxia as an important factor promoting progression of MM. In particular, hypoxia-triggered HIF-1 signaling was shown to promote chemoresistance, angiogenesis, invasiveness and induction of immature phenotype, suggesting that strategies targeting HIF-1 may contribute to improvement of anti-myeloma therapies.

methodsThe Western Blot and RT-PCR techniques were applied to analyze the influence of metformin on HIF-1 pathway in MM cells. To evaluate the effect of metformin on the growth of MM cell lines in normoxic and hypoxic conditions the MTT assay was used. The apoptosis induction in metformin treated hypoxic and normoxic cells was verified by Annexin V/PI staining followed by FACS analysis.

resultsOur results showed, for the first time, that metformin inhibits HIF-1 signaling in MM cells. Moreover, we demonstrated the effect of metformin to be mainly oxygen dependent, since the HIF-1 pathway was not significantly affected by metformin in anoxic conditions as well as after application of hypoxic mimicking compound, CoCl

conclusionsTaken together, our study indicates metformin as a promising candidate for developing new treatment strategies exploiting HIF-1 signaling inhibition to enhance the overall anti-MM effect of currently used therapies, that may considerably benefit MM patients.

Indexed as

ApoptosisCell HypoxiaCell Line, TumorHumansHypoxia-Inducible Factor 1MetforminMultiple MyelomaSignal TransductionTumor MicroenvironmentHypoxia-Inducible Factor 1MetforminHIF-1 pathwayMetforminMultiple myeloma

Identifiers

PMID32715434
PMCPMC7550387
OpenAlexW3045425613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.